solo para uso en investigación
Cat. No.: S2911
Estructura química
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| PC12 | Function assay | 0.5 μM | GO6983 blocked the effect of PMA on the activation of Akt and MAPK induced by IGF-1 | 10788447 | ||
| PC-3 | Function assay | 1 μM | 2 h | Gö6983 abrogates the TPA-induced RGFR transactivation response | 15897236 | |
| HCT116 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 | |
| HT29 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 | |
| KM20 | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 | |
| KM12C | Function assay | 2 μM | 8 h | attenuated PMA-induced FLIP mRNA expression | 16052516 | |
| Caco-2 | Function assay | 2 μM | 8 h | completely attenuated PMA-induced FLIP mRNA expression | 16052516 | |
| A549 | Function assay | 10 μM | 1 h | markedly inhibited ATPγS-stimulated NADPH oxidase activity and H2O2 and/or ROS generation | 23326583 | |
| HeLa | Function assay | 2 μM | 48 h | suppressed the effect of PMA on apicularen A-induced cytotoxicity | 24447339 | |
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | |||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | |||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | |||
| HEK293 | Function assay | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in human HEK293 cells transfected with rabbit L-type calcium channel subunits, IC50 = 20 μM. | ChEMBL | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 442.51 | Fórmula | C26H26N4O3 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 133053-19-7 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | GOE 6983, Gö 6983 | Smiles | CN(C)CCCN1C=C(C2=C1C=CC(=C2)OC)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54 | ||
|
In vitro |
DMSO
: 89 mg/mL
(201.12 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
PKCγ
(Cell-free assay) 6 nM
PKCα
(Cell-free assay) 7 nM
PKCβ
(Cell-free assay) 7 nM
PKCδ
(Cell-free assay) 10 nM
PKCζ
(Cell-free assay) 60 nM
|
|---|---|
| In vitro |
Go 6983 (300 μM) suppresses PKCμ auto-phosphorylation by 20% reduction in NIH3T3 transfected with PKCμ. In hearts reperfused with PMNs and this compound (100 nM), left ventricular developed pressure (LVDP) and the rate of LVDP recoveres to 89% and 74% of baseline values, respectively, significantly higher than PMNs alone. This chemical (100 nM) significantly reduces PMNs adherence to the endothelium and infiltration into the myocardium compared with Ischemia followed by reperfusion (I/R)+ PMN hearts, and significantly inhibits superoxide release from PMNs by 90%. It attenuates post-I/R cardiac contractile dysfunction in the presence of PMNs, which may be related in part to decreased superoxide production. This inhibitor significantly inhibits antigen-induced superoxide release from leukocytes of patients previously sensitized to tree pollen. It inhibited intracellular Ca(2+) accumulation in human vascular tissue, suggesting a mechanism for its vasodilator properties. This compound (1 μM) combined with Ro-31-8425 (390 nM) slightly inhibits Angiotensin II–induced PLD2 activity in PGSMCs. It is isoform-specific PKC inhibitor that target the ATP binding site. It inhibits ΔPfPKB activity with an IC50 of 1 μM. In this chemical (5 μM)-treated cells, the number of rings in the following cycle is markedly less compared with the control cultures. This treatment (5 μM) results in an almost 60% decrease in formation of new rings in P. falciparum cultures. |
| Ensayo de quinasa |
Ensayo de unión
|
|
Las reacciones de fosforilación se llevan a cabo en un volumen total de 100 μL, que contiene tampón C (50 mM Tris-HCl, pH 7,5, 10 mM β-mercaptoetanol), 4 mM MgCl2, 10 μg de PS, 100 nM de TPA, 5 μL de un extracto celular de Sf158 como fuente de PKCμ recombinante o de extractos celulares de Sf9 como fuente de otras isoenzimas PKC recombinantes, 10 μg de syntide 2 como sustrato y 35 μM de ATP que contiene 1 μCi de [γ-32P]ATP. En algunos experimentos, se omiten PS y TPA o se añaden varios inhibidores en las concentraciones indicadas en el texto. Después de la incubación durante 10 min a 30℃, la reacción se detiene transfiriendo 50 μL de la mezcla de ensayo a un trozo cuadrado de papel de fosfocelulosa de 20 mm, que se lava 3 veces en agua desionizada y dos veces en acetona. La radiactividad de cada papel se determina mediante recuento por centelleo líquido.
|
|
| In vivo |
Go6983 (22.0 μg/mouse, i.v.) strongly inhibits tumor metastasis by 51.2 % in a mouse pulmonary B16BL6 tumor model. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | PKCη / PKCα / PKCδ / PKCε |
|
22892130 |